Klinicheskiy sluchay: primenenie selektivnogo antagonistaretseptorov endotelina ambrizentana pri idiopaticheskoy legochnoy gipertenzii

Abstract

References

  1. Беленков Ю.Н., Чазова И.Е. Первичная легочная гипертензия. М.: Нолидж, 1999.
  2. Диагностика и лечение легочной гипертензии. Российские рекомендации ВНОК. М., 2007.
  3. Rubin et al. Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs 2002; 11: 991
  4. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-36.
  5. Clozel M. Endothelin receptor antagonists: current status and perspectives. J Cardiovasc Pharmacol 2000; 35: S65.
  6. Gali_ N, Badesch D, Oudiz R et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005; 46 (3): 529-35.
  7. Battistini B, Berthiaume N, Kelland NF et al. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med (Maywood). 2006; 231 (6): 653-95.
  8. Olschewski H, Galie N, Kramer M et al. Ambrisentan Improves Exercise Capacity and Time to Clinical Worsening in Patients with Pulmonary Arterial Hypertension: Results of the ARIES-2 Study. San Diego, CA: American Thoracic Society, 2006.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies